Vimarsana
Biggest News Aggregation in the World

Page 3 - Eu Union News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eu Union. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eu Union Today - Breaking & Trending Today

India working to develop HSN codes for certain varieties of rice - Vimarsana News

India working to develop HSN codes for certain varieties of rice

Officials said that India is in the process of developing new Harmonised System of Nomenclature (HSN) codes for specific rice varieties to facilitate exports of those traditionally not consumed domestically. Currently, all categories of non-basmati white rice are prohibited for export.

How will the Ukraine/Russia war pan out in 2024? - Vimarsana News

How will the Ukraine/Russia war pan out in 2024?

Many Russians are confident in their army, believe it will win the war, approve of their government, and Vladimir Putin has high approval ratings for the presidential election in March. So where does that leave Ukraine?

PKNP-PoABI awarded RM9.5mil grant by EU - Vimarsana News

PKNP-PoABI awarded RM9.5mil grant by EU

IPOH: A grant worth about RM9.5mil has been awarded to Perak State Development Corporation (PKNP) and Port of Antwerp-Bruges International (PoABI) to conduct a research on Malaysia’s attractiveness in the port and maritime sector.

Conference on EU & Regional Integration held at NUML - Vimarsana News

Conference on EU & Regional Integration held at NUML

Islamabad: International Conference on European Union as Model for Regional Integration: Lessons for South Asia was organized by the International Relations department of the National University of...

Luspatercept Approval Shifts Treatment Landscape of Anemia in Lower-Risk MDS - Vimarsana News

Luspatercept Approval Shifts Treatment Landscape of Anemia in Lower-Risk MDS

Uwe Platzbecker, MD, discusses how to navigate decisions for the first-line treatment of anemia in patients with lower-risk MDS in light of luspatercept’s approval, expands on key data from the COMMANDS trial, and addresses potential concerns from clinicians who are uncertain about when to utilize this agent in the frontline setting in clinical practice.